Jan Krijt

Dr. Jan Krijt


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2004 in Blood
Verified
Journal Article
Closed access
PDF file
JKJan Krijt
Jan Krijt
MVMartin Vokurka
Martin Vokurka
KCKo-Tung Chang
Ko-Tung Chang
ENEmanuel Necas
Emanuel Necas
Mutations of hepcidin (HAMP) and hemo-juvelin (HJV) genes have been recently demonstrated to result in juvenile hemochromatosis. Expression of HAMP is regulated by iron status or infection, whereas regulation of HJV is yet unknown. Using quantitative real-time polymerase chain reaction, we compared expression of Hamp and Rgmc (the murine ortholog of HJV) in livers of mice treated with iron, erythropoietin, or lipopolysaccharide (LPS), as well as during fetal and postnatal development. Iron overload increased Hamp expression without effect on Rgmc mRNA. Erythropoietin decreased Hamp mRNA, but Rgmc expression was unchanged. Hamp mRNA level decreased after birth by 4 orders of magnitude, without significant changes in Rgmc expression. Administration of LPS elevated Hamp mRNA levels, while markedly decreasing hepatic Rgmc mRNA levels (to ∼5% after 6 hours). The responses of Hamp and Rgmc were quite different and suggested that human HJV expression could be modulated by inflammation.

1 August 2011 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
JKJan Krijt
Jan Krijt
YFYuzo Fujikura
Yuzo Fujikura
ARAndrew J. Ramsay
Andrew J. Ramsay
GVGloria Velasco
Gloria Velasco
ENEmanuel Necas
Emanuel Necas

1 May 1993 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
JKJan Krijt
Jan Krijt
IHIneke van Holsteijn
Ineke van Holsteijn
IHIne Hassing
Ine Hassing
MVMartin Vokurka
Martin Vokurka
BBBas J. Blaauboer
Bas J. Blaauboer

17 August 2013 in Physiological Research
Verified
Journal Article
Closed access
JFJ. Frýdlová
J. Frýdlová
YFY. Fujikura
Y. Fujikura
MVM. Vokurka
M. Vokurka
ENE. Nečas
E. Nečas
JKJan Krijt
Jan Krijt
Matriptase-2, a membrane protein encoded by the Tmprss6 gene, is a negative regulator of hepcidin expression. Although matriptase-2 has been proposed to cleave membrane hemojuvelin, we have recently found decreased hemojuvelin protein levels in Tmprss6 -/- mice. The purpose of this study was to confirm this observation by determining hemojuvelin protein levels in another strain of mice with disrupted Tmprss6 gene, and to determine the effect of matriptase-2 deficiency on the expression of other membrane proteins participating in the bone morphogenetic protein signal transduction. Mask mice, which lack the proteolytic domain of matriptase-2, displayed decreased liver hemojuvelin protein content, while Id1 mRNA level, an indicator of hemojuvelin-dependent signal transduction, was increased. Protein levels of bone morphogenetic protein receptors Alk3 and Acvr2a were unchanged, and transferrin receptor 2 and neogenin protein levels were slightly decreased. The results confirm that the loss of matriptase-2 increases bone morphogenetic protein-dependent signaling, while paradoxically decreasing liver hemojuvelin protein content. The regulation of transferrin receptor 2 protein levels by transferrin saturation was not affected in mask mice. How the loss of matriptase-2 proteolytic activity leads to decreased hemojuvelin protein levels is at present unclear.

1 April 2010 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
JKJan Krijt
Jan Krijt
AJAnna Jonášová
Anna Jonášová
RNRadana Neuwirtová
Radana Neuwirtová
ENEmanuel Necas
Emanuel Necas

18 May 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JKJan Krijt
Jan Krijt
JFJana Frýdlová
Jana Frýdlová
LKLenka Kukačková
Lenka Kukačková
YFYuzo Fujikura
Yuzo Fujikura
PPPetr Prikryl
Petr Prikryl
ENEmanuel Necas
Emanuel Necas
Hemojuvelin (Hjv) is a key component of the signaling cascade that regulates liver hepcidin (Hamp) expression. The purpose of this study was to determine Hjv protein levels in mice and rats subjected to iron overload and iron deficiency. C57BL/6 mice were injected with iron (200 mg/kg); iron deficiency was induced by feeding of an iron-deficient diet, or by repeated phlebotomies. Erythropoietin (EPO)-treated mice were administered recombinant EPO at 50 U/mouse. Wistar rats were injected with iron (1200 mg/kg), or fed an iron-deficient diet. Hjv protein was determined by immunoblotting, liver samples from Hjv−/− mice were used as negative controls. Mouse plasma Hjv content was determined by a commercial ELISA kit. Liver crude membrane fraction from both mice and rats displayed a major Hjv-specific band at 35 kDa, and a weaker band of 20 kDa. In mice, the intensity of these bands was not changed following iron injection, repeated bleeding, low iron diet or EPO administration. No change in liver crude membrane Hjv protein was observed in iron-treated or iron-deficient rats. ELISA assay for mouse plasma Hjv did not show significant difference between Hjv+/+ and Hjv−/− mice. Liver Hamp mRNA, Bmp6 mRNA and Id1 mRNA displayed the expected response to iron overload and iron deficiency. EPO treatment decreased Id1 mRNA, suggesting possible participation of the bone morphogenetic protein pathway in EPO-mediated downregulation of Hamp mRNA. Since no differences between Hjv protein levels were found following various experimental manipulations of body iron status, the results indicate that, in vivo, substantial changes in Hamp mRNA can occur without noticeable changes of membrane hemojuvelin content. Therefore, modulation of hemojuvelin protein content apparently does not represent the limiting step in the control of Hamp gene expression.